RSS0393 is named as an intervention in 2 current clinical trials in our China register. None are recruiting at the moment. The most common phase is Phase 2. The sponsor with the most trials is Jiangsu HengRui Medicine Co., Ltd (1). The most-studied condition is Plaque Psoriasis in Children.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of RSS0393 Ointment in Adult Patients With Plaque Psoriasis.
NCT07543224 · ClinicalTrials.gov ↗ · Plaque Psoriasis Subjects
|
Phase 3 | Not yet open | Reistone Biopharma Company Limited | China |
|
A Clinical Study to Evaluate the Safety and Pharmacokinetics of Topical RSS0393 Ointment in Children and Adolescents With Plaque Psoriasis
NCT07102888 · ClinicalTrials.gov ↗ · Plaque Psoriasis in Children, Plaque Psoriasis in Adolescents
|
Phase 2 | Not yet open | Jiangsu HengRui Medicine Co., Ltd. | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Jiangsu HengRui Medicine Co., Ltd. | 1 |
| Reistone Biopharma Company Limited | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name RSS0393 as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Jiangsu HengRui Medicine Co., Ltd (1) and Reistone Biopharma Company Limited (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how RSS0393 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how RSS0393 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists RSS0393 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.